Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Pediatric Hematology/Oncology
•
Immune Checkpoint Inhibitor
•
Pediatric Oncology
How do you determine timing, and whether or not to rechallenge a pediatric oncology patient with immune checkpoint inhibitor therapy after development of irAE?
Related Questions
How would you advise a younger patient with residual/recurrent optic nerve meningioma, proceeding with radiotherapy, about the risks of malignant transformation or induction of other brain malignancies because of radiation?
What is your standard diagnostic workup to confirm GVHD in a patient post-BMT with skin rash and jaundice?
For what patients/diagnoses do you currently use sodium thiosulfate to reduce the risk of cisplatin associated ototoxicity?
What workup do you complete for a teenage patient presenting with an incidentally discovered adrenal mass?
If a pediatric patient has a prior history of cancer-associated thrombosis while receiving active treatment, can they be on estrogen-containing OCPs in the future?
Do you use prophylactic defibrotide in pediatric patients undergoing BMT who are considered to be at high risk for the development of VOD/SOS?
How do you approach adjuvant therapy for resected Stage I Ewing sarcoma of the kidney?
In platinum-refractory or multiply-relapsed NSGCT with 1–2 progressive sites and no good surgical option, is there a role for local radiotherapy (e.g., SBRT) to those sites?
What is your approach to patients/parents seeking alternative or complementary treatment in pediatric oncology patients?
How do you approach revaccination after chemotherapy, and what labs (if any) do you use to assess immune reconstitution?
